Show simple item record

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study

dc.contributor.authorFeyerabend, Susan
dc.contributor.authorRoubaud, Guilhem
dc.contributor.authorOezgueroglu, Mustafa
dc.contributor.authorPenel, Nicolas
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorMehra, Niven
dc.contributor.authorKolinsky, Michael P.
dc.contributor.authorProcopio, Giuseppe
dc.contributor.authorJoung, Jae Young
dc.contributor.authorGravis, Gwenaelle
dc.contributor.authorNishimura, Kazuo
dc.contributor.authorGedye, Craig
dc.contributor.authorPadua, Charles
dc.contributor.authorShore, Neal
dc.contributor.authorThiery-Vuillemin, Antoine
dc.contributor.authorSaad, Fred
dc.contributor.authorvan Alphen, Robbert
dc.contributor.authorCarducci, Michael A.
dc.contributor.authorDesai, Chintu
dc.contributor.authorBrickel, Neil
dc.contributor.authorPoehlein, Christian
dc.contributor.authorDel Rosario, Paula
dc.contributor.authorFizazi, Karim
dc.date.accessioned2022-07-04T15:45:13Z
dc.date.available2022-07-04T15:45:13Z
dc.identifier.citationRoubaud G., Oezgueroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , Procopio G., Feyerabend S., Joung J. Y. , Gravis G., et al., "Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study", EUROPEAN JOURNAL OF CANCER, cilt.170, ss.73-84, 2022
dc.identifier.issn0959-8049
dc.identifier.otherav_c0b6b3db-73be-4358-9868-6316c5647bc1
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/184524
dc.identifier.urihttps://doi.org/10.1016/j.ejca.2022.04.016
dc.description.abstractBackground: Based on PROfound, olaparib is approved for patients with metastatic castration-resistant prostate cancer following disease progression on at least enzalutamide or abiraterone and who carry relevant alterations in DNA repair genes. To facilitate continued olaparib treatment as long as the patient derives benefit, we describe further safety assessments from PROfound focusing on the four most common adverse events (AEs) and events of special interest.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleOlaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF CANCER
dc.contributor.departmentInst Bergonie , ,
dc.identifier.volume170
dc.identifier.startpage73
dc.identifier.endpage84
dc.contributor.firstauthorID3433990


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record